

AMENDMENTS TO THE CLAIMS

The following list of claims replaces all prior versions, or listings, of claims in this application.

Please amend the claims as follows:

1. (Currently Amended) A method of therapeutically treating interstitial cystitis ("IC"), comprising: administering to an ~~affected~~ interstitial cystitis-afflicted subject a pharmaceutically effective amount of a composition comprising an ~~RDP58~~ oligopeptide, wherein said oligopeptide comprises the amino acid sequence set forth as SEQ ID NO:28.
2. (Currently amended) The method of Claim 1, wherein the ~~RDP58~~ oligopeptide consists of the amino acid sequence set forth as SEQ ID NO:28.
3. (Original) The method of Claim 1, wherein at least one of the terminal amino acids is a modified amino acid.
4. (Original) The method of Claim 3, wherein the modified amino acid is an amidated amino acid or salts thereof.
5. (Currently amended) The method of Claim 1, wherein one or more of the amino acids of the oligopeptide are D isomers.
6. (Currently Amended) The method of Claim 5, wherein all the amino acids of the oligopeptide, other than glycine, are the D-isomer.
7. (Original) The method of Claim 1, wherein administering is by intravesicle instillation.
8. (Canceled)
9. (Canceled)

10. (Currently Amended) A method of treating interstitial cystitis, comprising contacting ~~disease-affected~~ tissue or cells affected by IC with a pharmaceutically effective amount of a composition comprising an ~~RDP58~~-oligopeptide, wherein said oligopeptide comprises the amino acid sequence set forth as SEQ ID NO:28 to ameliorate a manifestation of interstitial cystitis.
11. (Original) The method of Claim 10, wherein the manifestation is histamine release and the cells are mast cells.
12. (Original) The method of Claim 10, wherein the manifestation is Substance P expression.
13. (Canceled)
14. (Canceled)
15. (Original) The method of Claim 10, wherein the manifestation is degradation of urine/blood barrier.
16. (Currently amended) The method according to any one of claims 10-15, wherein the ~~RDP58~~-oligopeptide consists of the amino acid sequence set forth as SEQ ID NO:28.
17. (Original) The method of Claim 16, wherein one or more of the amino acids of the oligopeptide are the D-isomer.
18. (Currently Amended) The method of Claim 17, wherein all the amino acids of the oligopeptide, other than glycine, are the D-isomer.
19. (Original) The method of Claim 16, wherein at least one terminal amino acid residue is a modified amino acid.
20. (Original) The method of Claim 19, wherein the modified amino acid is an amidated amino acid or salts thereof.